Barron’s: Bill Smead on Amgen
This Biotech Stock Is a Remedy for Tougher Times By Al Root For more information go to www.barrons.com. Stocks mentioned: AMGN The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no
November 16, 2018
